Journals
Consult the user guide
For assistance, please contact us
Consult the user guide
For assistance, please contact us
Add search criteria
Results: 1 - 15 of 65
2019-08-21 [p.5755]
— No. 421-04217 concerning the regulation of food and drugs. — Sessional Paper No. 8545-421-215-10;
2019-07-18 [p.5746]
— Nos. 421-03745, 421-03746, 421-03747, 421-03748, 421-04484, 421-04485 and 421-04486 concerning the regulation of food and drugs. — Sessional Paper No. 8545-421-215-09;
2019-06-14 [p.5593]
— by Mr. Johns (Courtenay—Alberni), three concerning the regulation of food and drugs (Nos. 421-04484 to 421-04486) and one concerning housing policy (No. 421-04487);
2019-06-07 [p.5477]
— by Ms. Hardcastle (Windsor—Tecumseh), one concerning the protection of the environment (No. 421-04216) and one concerning the regulation of food and drugs (No. 421-04217);
2019-05-30 [p.5383]
— No. 421-03507 concerning the regulation of food and drugs. — Sessional Paper No. 8545-421-215-08;
2019-05-27 [p.5336]
— No. 421-03341 concerning the regulation of food and drugs. — Sessional Paper No. 8545-421-215-07;
2019-05-14 [p.5300]
— by Mr. Johns (Courtenay—Alberni), four concerning the regulation of food and drugs (Nos. 421-03745 to 421-03748);
2019-05-03 [p.5232]
— by Ms. Blaney (North Island—Powell River), one concerning the pension system (No. 421-03506), one concerning the regulation of food and drugs (No. 421-03507) and one concerning cellphone towers (No. 421-03508);
2019-04-09 [p.5118]
— by Mr. Johns (Courtenay—Alberni), one concerning the regulation of food and drugs (No. 421-03341);
2019-01-28 [p.4499]
— No. 421-03032 concerning the regulation of food and drugs. — Sessional Paper No. 8545-421-215-05;
2019-01-28 [p.4523]
Q-2129 — Mr. Dubé (Beloeil—Chambly) — With regard to Health Canada’s re-evaluation decisions, including RVD2017-01, Glyphosate, and the “Monsanto Papers”: (a) how many and which studies are currently being re-evaluated by Health Canada; (b) for each of the studies in (a), when did Health Canada make the decision to re-evaluate it; (c) has Health Canada verified the independence of the studies in (a); (d) if the answer to (c) is affirmative, what was the detailed process for verifying the independence of the studies; and (e) does Health Canada have information that approved independent studies were written by Monsanto and, if so, since what date, broken down by study? — Sessional Paper No. 8555-421-2129.
2019-01-16 [p.4486]
— No. 421-03060 concerning the regulation of food and drugs. — Sessional Paper No. 8545-421-215-04;
2018-12-07 [p.4434]
— by Mr. Johns (Courtenay—Alberni), one concerning the regulation of food and drugs (No. 421-03060);
2018-12-03 [p.4392]
— by Mr. Johns (Courtenay—Alberni), one concerning the regulation of food and drugs (No. 421-03032);
2018-11-28 [p.4369]
Q-1978 — Ms. Quach (Salaberry—Suroît) — With respect to Lyme disease-carrying ticks and Lyme disease in Canada: (a) what percentage of Lyme disease cases are thought to be reported; (b) what percentage of people who receive treatment for Lyme disease develop post-treatment Lyme disease syndrome; (c) what percentage of people with untreated Lyme disease infections experience intermittent bouts of arthritis; (d) what percentage of untreated Lyme disease patients are at risk of developing chronic neurological complaints months to years after infection; (e) based on all epidemiological data collected since Lyme disease became a nationally reportable disease, what is the most recent data available about Lyme disease cases, broken down by (i) province, (ii) month, (iii) symptom, (iv) incidence by age and sex; (f) what is Lyme disease’s (i) ranking among vector-borne diseases in Canada, (ii) ranking among nationally notifiable diseases; (g) is it possible to have more than one tick-borne infection, and, if so, (i) are possible co-infections being investigated and tracked, (ii) does one’s chance of having multiple tick-borne infections depend on geographic location, and, if so, what areas are particularly at risk, (iii) what is the rate of co-infection by province; (h) since 2012, how has a warming climate impacted Lyme disease, in particular, (i) how has warming impacted tick distribution by province, (ii) how has warming impacted the distribution of Lyme disease by province; (i) what does the government project will be the effect of climate change on (i) the geographical range of ticks in 2020 and 2050, (ii) the distribution of ticks across Canada, (iii) human Lyme disease infections, (iv) the distribution of Lyme disease infections in Canada; (j) what are Health Canada’s recommended treatment guidelines for Lyme disease, and what was the process used to develop them; (k) what tests does Health Canada recommend for diagnosing cases of Lyme disease; (l) what is the percentage accuracy of the recommended tests in (k) at each stage of disease, namely, when a patient has an erythema migrans rash, when a patient is in the early disseminated stage (days to weeks post-tick bite), and when a person is in the late disseminated stage (months to years post-tick bite); (m) what tests for diagnosing Lyme disease are available and recommended in Canada during each of the stages of the disease mentionned in (l); (n) can patients be treated based solely on their symptoms or must they have had positive test results; (o) is the government aware of any organization that recommends physicians who are familiar with diagnosing and treating Lyme disease, and, if so, where can this information be accessed; (p) what percentage of patients with Lyme disease respond well to antibiotics; (q) what percentage of patients with Lyme disease experience fatigue, muscle aches, sleep disturbance, or difficulty thinking even after completing a recommended course of antibiotic treatment; (r) what research has been undertaken regarding the benefits and risks of a longer course of antibiotics; (s) what follow-up has Health Canada undertaken to ensure that patients have access to a longer course of antibiotic treatment if required; (t) what are Health Canada’s recommendations and treatment, if any, concerning those who suffer post-treatment Lyme disease syndrome; (u) do these individuals in (t) have access to medical means (drugs or other) to provide relief even if their symptoms are neither known nor written in a nomenclature; (v) if there is no treatment or recommendation, is research underway to help these patients in (t); (w) what resources, if any, does Health Canada provide to clinicians regarding diagnosis, treatment, and testing; (x) what resources, if any, does Health Canada provide to clinicians for continuing medical education on the topic of Lyme disease; (y) what, if any, case definition and report forms does Health Canada make available concerning Lyme disease, and when were each of these forms last updated by Health Canada; (z) what specific actions are Health Canada and the Canadian Institutes of Health Research undertaking regarding prevention of Lyme disease, including, but not limited to, (i) programs of research, (ii) programs of service, (iii) education programs for the public and health care providers; (aa) what resources have been provided to each initiative identified in response to (z); (bb) what, if anything, is Health Canada doing with national surveillance data regarding Lyme disease, in particular, (i) what is it doing to maintain such data, (ii) what is it doing to analyze such data, (iii) what resources has it allocated to such activities; (cc) in what epidemiologic investigations on Lyme disease is the government currently involved in some capacity; (dd) what financial resources is the government providing for any such study in (cc); (ee) with regard to diagnostic and reference laboratory services studying Lyme disease, does the government have this expertise, broken down by agency and by expenditures since 2015; (ff) if the answer to (ee) is negative, does the government fund provinces or agencies, broken down by (i) agency name, (ii) expenditures since 2015, (iii) type of agency (public or private); (gg) are the provinces following Health Canada’s diagnostic recommendations, and, if they are not following them, why not; and (hh) what, if any, steps is Health Canada and the Canadian Institute for Health Research taking to develop and test strategies for the control and prevention of Lyme disease in humans? — Sessional Paper No. 8555-421-1978.
Results: 1 - 15 of 65 | Page: 1 of 5

1
2
3
4
5
>
>|
Export As: XML CSV RSS

For more data options, please see Open Data